Name: An Introduction to Biomarker Testing in Metastatic Colorectal Cancer
Uploaded: 2023-02-16T14:00:23.471Z
Description: Tanios S. Bekaii-Saab, MD, FACP introduces the metastatic colorectal cancer (mCRC) treatment landscape and the emphasizes importance of biomarker testing in patients with mCRC.

Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Oncology Nursing News

Pediatric Oncology

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

Sarcomas/TGCT

Supportive Care

Belumosudil elicited sustained responses and generated no new safety signals in patients with chronic graft-vs-host disease.

Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD

Itacitinib prophylaxis showed signals for reducing CRS and ICANS following treatment with axicabtagene ciloleucel in patients with B-cell lymphoma. 

Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma

Serial testing of ctDNA could improve risk stratification for determining adjuvant treatment in patients with high-risk muscle-invasive bladder cancer.

Serial ctDNA Testing Could Improve Risk Stratification in High-Risk MIBC

Adjuvant nivolumab extended DFS, NUTRFS, and DMFS vs placebo and showed for the first time an improvement in OS in patients with high-risk muscle-invasive urothelial cancer. 

Adjuvant Nivolumab Provides Sustained DFS Benefit, Favors OS in Muscle-Invasive Urothelial Cancer

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Articles

The FDA has approved alectinib as adjuvant treatment in select patients with ALK-positive non–small cell lung cancer.

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC

Matthew S. Johnson, MD, discusses a pilot study of Y-90 radioembolization plus pembrolizumab in patients with poor-prognosis hepatocellular carcinoma.

Y-90 Radioembolization Plus Pembrolizumab Generates Early Efficacy Signals in HCC

Experts discuss the FDA's call for a boxed warning for secondary T-cell malignancies on all approved CAR T-cell agents in late January 2024.

Call for Boxed Warning for Secondary Malignancies on CAR T-Cell Therapies Raises Alarm, But Key Questions Remain

Eric S. Christenson, MD, discusses the potential benefit of copanlisib plus nivolumab in PIK3CA-mutant microsatellite stable colorectal cancer. 

Early Data With Copanlisib/Nivolumab Combo Support Further Exploration in MSS CRC

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Post-Conference Perspectives: Updates in Colorectal Cancer: Highlights from ASCO GI 2023 and Beyond

Videos

Tanios S. Bekaii-Saab, MD, FACP describes the current colorectal cancer (CRC) treatment landscape, shares relevant updates from the American Society for Clinical Oncology’s Gastrointestinal Cancers Symposium 2023, and discusses his hopes for the future of the field.

Tanios S. Bekaii-Saab, MD, FACP introduces the metastatic colorectal cancer (mCRC) treatment landscape and the emphasizes importance of biomarker testing in patients with mCRC.

An Introduction to Biomarker Testing in Metastatic Colorectal Cancer 

An expert in gastrointestinal cancers reviews outcomes from the MOUNTAINEER clinical trial, focusing on concordance analysis data for HER2 testing as well as the efficacy of tucatinib and trastuzumab.

Clinical Trial Review: MOUNTAINEER

Clinical insights regarding the design, patient population, and overall aims of the ongoing phase 3 clinical trial MOUNTAINEER-03.

MOUNTAINEER-03 Clinical Trial Study Design and Implications

Discussion centered around emerging treatment options for patients with HER2+ mCRC, including trastuzumab deruxtucan.

Emerging Treatment Options for Patients with HER2+ Metastatic Colorectal Cancer

Dr Tanios S. Bekaii-Saab closes the discussion with key unmet needs in the mCRC treatment landscape. 

The Future of the Metastatic Colorectal Cancer Treatment Landscape

An Introduction to Biomarker Testing in Metastatic Colorectal Cancer

EP: 1.An Introduction to Biomarker Testing in Metastatic Colorectal Cancer

EP: 2.Clinical Trial Review: MOUNTAINEER

EP: 3.MOUNTAINEER-03 Clinical Trial Study Design and Implications

EP: 4.Emerging Treatment Options for Patients with HER2+ Metastatic Colorectal Cancer

EP: 5.The Future of the Metastatic Colorectal Cancer Treatment Landscape

Latest Conference Coverage